Richard Yarwood, group president of Catalent's Sterile Technologies segment, said: “With this first FDA product approval, we are even more strongly positioned to help our customers satisfy the fast growing US market demand for drugs and biologics in pre-filled syringe format."
In June, a report by the Freedonia Group predicted that the US market for primary pharmaceutical containers, which includes pre-fillable syringes, will be worth $9.6bn by 2012, driven by the emergence of new biologic therapies.
